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INTRODUCTION 
In the era of novel drug delivery system (NDDS) emphasis 
is given on spatial placement of drug for chronic 
conditions. Targeted delivery of anticancer and anti-
infective drugs appears to be challenging but achievable 
task with the use of novel drug delivery systems. Different 
novel approaches used for delivering these drugs include 
liposomes, microspheres, nanotechnology, micro-
emulsion, antibody-loaded drug delivery, magnetic 
microcapsules, implantable pumps and niosomes 1. 
Niosomes or non-ionic surfactant vesicles are microscopic 
lamellar structures formed on admixture of non-ionic 
surfactant of the alkyl or dialkyl polyglycerol ether class 
and cholesterol with subsequent hydration in aqueous 
media2.Niosomes can be changed or modified by the 
incorporation of other excipients like cholesterol, into the 
membrane and they can possess one or more lipid bilayers 
encapsulating an aqueous core. A diverse range of 
materials have been used to form Niosomes such as 
sucrose ester surfactants and polyoxyethylene alkyl ether 
surfactants. 
Niosome vesicles were prepared with the thin layer 
evaporation method and were physicochemically 
characterized. In comparison with classical formulations 
such as emulsions, these systems exhibit lower toxicity and 
permit closer control of the availability of active 
substances at the stratum corneum. Niosomes may act as a 
depot, releasing the drug in a controlled manner. The 
therapeutic performance of the drug molecules can also be 
improved by delayed clearance from the circulation,      
 
protecting the drug from biological environment and 
restricting effects to target cells3. It can also be used as 
vehicle for poorly absorbable drugs to design the novel 
drug delivery system. It enhances the bioavailability by 
crossing the anatomical barrier of gastrointestinal tract via 
transcytosis of M cells of Peyer's patches in the intestinal 
lymphatic tissues4. 
The niosomal vesicles are taken up by reticulo-endothelial 
system. Such localized drug accumulation is used in 
treatment of diseases, such as leishmaniasis, in which 
parasites invade cells of liver and spleen5. Some non-
reticulo-endothelial systems like immunoglobulins also 
recognize lipid surface of this delivery system6. 
Encapsulation of various anti-neoplastic agents in this 
carrier vesicle has minimized drug-induced toxic side 
effects while maintaining, or in some instances, increasing 
the anti-tumour efficacy7. Many drugs are administered 
through niosomes via transdermal route to improve the 
therapeutic efficacy. 
Niosomes provides better drug concentration at the site of 
action administered by oral, parenteral and topical routes. 
The evolution of niosomal drug delivery technology is still 
at the stage of infancy, but this type of drug delivery 
system has shown promise in cancer chemotherapy and 
anti-leishmanial therapy. In niosomes, the vesicles forming 
amphiphile is a non-ionic surfactant such as Span – 60 
which is usually stabilized by addition of cholesterol and 
small amount of anionic surfactant such as dicetyl 
phosphate8. 
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TYPES OF NIOSOMES 
 Based on the vesicle size, niosomes can be divided into 
three groups: 
 (i) Small Unilamellar Vesicles (SUV, Size=0.025-0.05 
μm), 
 (ii) Multilamellar Vesicles (MLV, Size=>0.05 μm), 
 (iii) Large Unilamellar Vesicles (LUV, Size=>0.10 μm). 
Niosomes In Lieu Of Liposomes – Reasons 
One of the most significant problems associated with the 
use of liposomes as adjuvant is the susceptibility of 
phospholipids to oxidative degradation in air. This requires 
that purified phospholipids and liposomes have to be 
stored and handled in an inert (e.g. nitrogen) atmosphere9. 
Phospholipid raw materials are naturally occurring 
substances and as such require extensive purification thus 
making them costly.Alternatively, phospholipids can be 
synthesised de novo, however this approach tends to be 
even more costly than using naturally occurring 
lipids.Because of liposomes above mentionioned 
drawbacks, alternative nonionic surfactants have been 
investigated. This involves formation of liposome-like 
vesicles from the hydrated mixtures of cholesterol and 
nonionic surfactant such as monoalkyl or dialkyl 
polyoxyethylene ether36. Niosomes are unilamellar or 
multilamellar vesicles capable of entrapping hydrophilic 
and hydrophobic solutes10.From a technical point of view, 
niosomes are promising drug carriers as they possess 
greater stability and lack of many disadvantages associated 
with liposomes, such as high cost and the variable purity 
problems of phospholipids11. Another advantage is the 
simple method for the routine and large-scale production 
of niosomes without the use of unacceptable solvents. 
Cholesterol, 5-cholesten-3β-ol is used in combination with 
nonionic surfactant for the formation of niosomes. 
Advantages of Niosomes 
•    Since the structure of the niosome offers place to 
accommodate hydrophilic, lipophilic as well as 
ampiphilic drug moieties, they can be used for a variety 
of drugs. 12 
•    Niosomes exhibits flexibility in their structural 
characteristics (composition, fluidity and size) and can 
be designed according to the desired situation. 
•    They improve the therapeutic performance of the 
drug by protecting it from the biological environment 
and restricting effects to target cells, thereby reducing 
the clearance of the drug. 
•    Niosomes can act as a depot to release the drug 
slowly and offer a controlled release. 
•    They can increase the oral bioavailability of drugs. 
•    They are osmotically active and stable. 
•    They increase the stability of the entrapped drug. 
•    They can enhance the skin penetration of drugs. 
•    They can be made to reach the site of action by oral, 
parenteral as well as topical routes. 
•    The surfactants are biodegradable, biocompatible, 
and non-immunogenic. 
•    The niosomal dispersions in an aqueous phase can 
be emulsified in a non-aqueous phase to control the 
release rate of the drug and administer normal vesicles 
in external non-aqueous phase. 
•    Handling and storage of surfactants do not require 
any special conditions. 
•    The vesicle suspension being water based offers 
greater patient compliance over oily dosage forms. 
METHODS OF PREPARATION OF NIOSOMES 
 Preparation of vesicles: The preparation methods should 
be chosen according to the use of niosomes, since the 
preparation methods influence the numbers of bilayers, 
size, size distribution and entrapment efficiency of the 
aqueous phase and the membrane permeability of the 
vesicles.  
1. Ether injection method 
This method provides a means of making niosomes by 
slowly introducing a solution of surfactant dissolved in 
diethyl ether into warm water maintained at 60°C. The 
surfactant mixture in ether is injected through 14-gauge 
needle into an aqueous solution of material. Vaporization 
of ether leads to formation of single layered vesicles. 
Depending upon the conditions used the diameter of the 
vesicle range from 50 to 1000 nm. 13 
2. Hand shaking method (Thin film hydration 
technique) 
The mixture of vesicles forming ingredients like surfactant 
and cholesterol are dissolved in a volatile organic solvent 
(diethyl ether, chloroform or methanol) in a round bottom 
flask. The organic solvent is removed at room temperature 
(20°C) using rotary evaporator leaving a thin layer of solid 
mixture deposited on the wall of the flask. The dried 
surfactant film can be rehydrated with aqueous phase at 0-
60°C with gentle agitation. This process forms typical 
multilamellar niosomes.  
Thermosensitive niosomes were prepared by Raja Naresh 
et al14 by evaporating the organic solvent at 60°C and 
leaving a thin film of lipid on the wall of rotary flash 
evaporator. The aqueous phase containing drug was added 
slowly with intermittent shaking of flask at room 
temperature followed by sonication.  
3. Sonication 
A typical method of production of the vesicles is by 
sonication of solution as described by Cable 15. In this 
method an aliquot of drug solution in buffer is added to the 
surfactant/cholesterol mixture in a 10-ml glass vial. The 
mixture is probe sonicated at 60°C for 3 minutes using a 
sonicator with a titanium probe to yield niosomes.  
4. Micro fluidization 
Micro fluidization is a recent technique used to prepare 
unilamellar vesicles of defined size distribution. This 
method is based on submerged jet principle in which two 
fluidized streams interact at ultra-high velocities, in 
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precisely defined micro channels within the interaction 
chamber. The impingement of thin liquid sheet along a 
common front is arranged such that the energy supplied to 
the system remains within the area of niosomes formation. 
The result is a greater uniformity, smaller size and better 
reproducibility of niosomes formed. 16 
5. Multiple membrane extrusion method  
Mixture of surfactant, cholesterol and dicetyl phosphate in 
chloroform is made into thin film by evaporation. The film 
is hydrated with aqueous drug solution and the resultant 
suspension extruded through polycarbonate membranes, 
which are placed in series for upto 8 passages. It is a good 
method for controlling niosome size.  
6. Reverse Phase Evaporation Technique (REV) 
Cholesterol and surfactant (1:1) are dissolved in a mixture 
of ether and chloroform. An aqueous phase containing 
drug is added to this and the resulting two phases are 
sonicated at 4-5°C. The clear gel formed is further 
sonicated after the addition of a small amount of phosphate 
buffered saline (PBS). The organic phase is removed at 
40°C under low pressure. The resulting viscous niosome 
suspension is diluted with PBS and heated on a water bath 
at 60°C for 10 min to yield niosomes.  
Raja Naresh et al have reported the preparation of 
Diclofenac Sodium niosomes using Tween 85 by this 
method.  
7. Trans membrane pH gradient (inside acidic) Drug 
Uptake Process (remote Loading) 
Surfactant and cholesterol are dissolved in chloroform. 
The solvent is then evaporated under reduced pressure to 
get a thin film on the wall of the round bottom flask. The 
film is hydrated with 300 mM citric acid (pH 4.0) by 
vortex mixing. The multilamellar vesicles are frozen and 
thawed 3 times and later sonicated. To this niosomal 
suspension, aqueous solution containing 10 mg/ml of drug 
is added and vortexed. The pH of the sample is then raised 
to 7.0-7.2 with 1M disodium phosphate. This mixture is 
later heated at 60°C for 10 minutes to give niosomes. 17 
8. The “Bubble” Method 
It is novel technique for the one step preparation of 
liposomes and niosomes without the use of organic 
solvents. The bubbling unit consists of round-bottomed 
flask with three necks positioned in water bath to control 
the temperature. Water-cooled reflux and thermometer is 
positioned in the first and second neck and nitrogen supply 
through the third neck. Cholesterol and surfactant are 
dispersed together in this buffer (pH 7.4) at 70°C, the 
dispersion mixed for 15 seconds with high shear 
homogenizer and immediately afterwards “bubbled” at 
70°C using nitrogen gas. 18 
9. Formation of niosomes from proniosomes 
Another method of producing niosomes is to coat a water-
soluble carrier such as sorbitol with surfactant. The result 
of the coating process is a dry formulation. In which each 
water-soluble particle is covered with a thin film of dry 
surfactant. This preparation is termed “Proniosomes”. The 
niosomes are recognized by the addition of aqueous phase 
at T > Tm and brief agitation.  
T = Temperature. 
Tm = mean phase transition temperature.  
 
Figure 1: Formation of niosomes from proniosomes. 
Blazek-Walsh A.I. et al have reported the formulation of 
niosomes from maltodextrin based proniosomes. This 
provides rapid reconstitution of niosomes with minimal 
residual carrier. Slurry of maltodextrin and surfactant was 
dried to form a free flowing powder, which could be 
rehydrated by addition of warm water. 19 
DIFFERENT FORMULATIONS OF NIOSOMES 
1. Discomes. 
2. Niosomes vesicles in water/oil systems. 
3. Proniosomes. 
4. Niosomal dispersions. 
5. Polymer coated niosomes 
Characterization of Niosomes 
Size 
Shape of niosomal vesicles is assumed to be spherical, and 
their mean diameter can be determined by using laser light 
scattering method20.Also, diameter of these vesicles can be 
determined by using electron microscopy, molecular sieve 
chromatography, ultracentrifugation, photon correlation 
microscopy and optical microscopy  and.freeze fracture 
electron microscopy. Freeze thawing of niosomes 
increases the vesicle diameter, during the cycle. 
Vesicle Charge 
The vesicle surface charge can play an important role in 
the behavior of niosomes in vivo and in vitro.21 
Bilayerformation 
Assembly of non-ionic surfactants to form a bilayer vesicle 
is characterised by an X-cross formation under light 
polarisation microscopy22. 
Numberoflamellae 
This is determined by using nuclear magnetic resonance 
(NMR) spectroscopy, small angle X-ray scattering and 
electron microscopy. 
Membrane rigidity 
Membrane rigidity can be measured by means of mobility 
of fluorescence probe as a function of temperature. 
Entrapment efficiency 
After preparing niosomal dispersion, unentrapped drug is 
separated and the drug remained entrapped in niosomes is 
determined by complete vesicle disruption using 50% n-
propanol or 0.1% Triton X-100 and analysing the resultant 
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solution by appropriate assay method for the drug23.It can 
be represented as :-  
Entrapment efficiency (EF) = (Amount entrapped / total 
amount) Χ 100 
In vitro Release Study 
A method of in vitro release rate study was reported with 
the help of dialysis tubing24. A dialysis sac was washed 
and soaked in distilled water. The vesicle suspension was 
pipetted into a bag made up of the tubing and sealed. The 
bag containing the vesicles was then placed in 200 ml 
buffer solution in a 250 ml beaker with constant shaking at 
25°C or 37°C. At various time intervals, the buffer was 
analysed for the drug content by an appropriate assay 
method.In another method, isoniazid-encapsulated 
niosomes were separated by gel filtration on Sephadex G- 
50 powder kept in double distilled water for 48 h for 
swelling25. At first, 1 ml of prepared niosome suspension 
was placed on the top of the column and elution was 
carried out using normal saline. Niosomes encapsulated 
isoniazid elutes out first as a slightly dense, white 
opalescent suspension followed by free drug. Separated 
niosomes were filled in a dialysis tube to which a sigma 
dialysis sac was attached to one end. The dialysis tube was 
suspended in phosphate buffer of pH (7.4), stirred with a 
magnetic stirrer, and samples were withdrawn at specific 
time intervals and analysed using high-performance liquid 
chromatography (HPLC) method.  
In vivo Release Study 
Albino rats were used for this study. These rats were 
subdivided with groups. Niosomal sspension used for in 
vivo study was injected intravenously (through tail vein) 
using appropriate disposal syringe. 
FACTORS AFFECTING FORMATION OF 
NIOSOMES 
Nature of surfactants 
A surfactant used for preparation of niosomes must have 
hydrophilic head and hydrophobic cases single steroidal 
group26.The ether type surfactants with single chain alkyl 
as hydrophobic tail is more toxic than corresponding 
dialkyletherchain27. The ester type surfactants are 
chemically less stable than ether type surfactants and the 
former is less toxic than the latter due to ester-linked 
surfactant degraded by esterases to triglycerides andfatty 
acid in vivo. The surfactants with alkyl chain length from 
C12-C18 are suitable for preparation of noisome. 
Surfactants such as C16EO5 (poly-oxyethylene cetyl ether) 
or C18EO5 (polyoxyethylene steryl ether) are used for 
preparation of polyhedral vesicles28.Span series surfactants 
having HLB number of between 4 and 8 can form vesicles. 
Structure of surfactants 
The geometry of vesicle to be formed from surfactants is 
affected by its structure, which is related to critical packing 
parameters. On the basis of critical packing parameters of 
Surfactants can predicate geometry of vesicle to be 
formed. Critical packing parameters can be defined using 
following equation, 
CPP (Critical Packing Parameters) = v/lc ×a0 
Where v = hydrophobic group volume,, lc = the critical 
hydrophobic group length,, a0= the area of hydrophilic 
head group. 
From the critical packing parameter value type of miceller 
structure formed can be ascertained as given below, 
If CPP < ½ then formation of spherical micelles, 
If ½ < CPP < 1 formation of bilayer micelles, 
If CPP > 1 formation inverted micelles. 
Membrane composition 
The stable niosomes can be prepared with addition of 
different additives along with surfactants and drugs. 
Niosomes formed have a number of morphologies and 
their permeability and stability properties can be altered by 
manipulating membrane characteristics by different 
additives. In case of polyhedral niosomes formed from 
C16G2, the shape of these polyhedral niosome remains 
unaffected by adding low amount of solulan C24 
(cholesteryl poly-24-oxyethylene ether), which prevents 
aggregation due to development of steric hindrance.In 
contrast spherical Niosomes are formed by C16G2: 
cholesterol:solulan (49:49:2). The mean size of niosomes 
is influenced by membrane composition such as 
Polyhedral niosomes formed by C16G2: solulan C24 in 
ratio (91:9) having bigger size (8.0 ± 0.03mm) than 
spherical/tubular niosomes formed by C16G2: 
cholesterol:solulan C24 in ratio (49:49:2) (6.6±0.2mm)29. 
Addition of cholesterol molecule to niosomal 
systemprovides rigidity to the membrane and reduces the 
leakage of drug from noisome30. 
Nature of encapsulated drug 
The physico-chemical properties of encapsulated drug 
influence charge and rigidity of the niosome bilayer. The 
drug interacts with surfactant head groups and develops 
the charge that creates mutual repulsion between surfactant 
bilayers and hence increases vesicle size31. The 
aggregation of vesicles is prevented due to the charge 
development on bilayer. 
Temperature of hydration 
Hydration temperature influences the shape and size of the 
noisome. For ideal condition it should be above the gel to 
liquid phase transition temperature of system. Temperature 
change of niosomal system affects assembly of surfactants 
into vesicles and also induces vesicle shape 
transformation. Arunothayanun et al. reported that a 
polyhedral vesicle formed by C16G2: solulan C24 (91:9) 
at 25°C which on heating transformed into spherical 
vesicle at 48°C, but on cooling from 55°C, the vesicle 
produced a cluster of smaller spherical niosomes at 49°C 
before changing to the polyhedral structures at 35°C. In 
contrast vesicle formed by C16G2: cholesterol: solulanC24 
(49:49:2) shows no shape transformation on heating or 
cooling. Along with the above mentioned factors, volume 
of hydration medium and time of hydration of niosomes 
are also critical factors. Improper selection of these factors 
may result in formation of fragile niosomes or creation of 
drug leakage problems. 
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THERAPEUTIC APPLICATIONS OF NIOSOMES 
Niosomal drug delivery is potentially applicable to many 
pharmacological agents for their action against various 
diseases. Some of their therapeutic applications are 
discussed below. 
Targeting of bioactive agents 
To reticulo-endothelial system (RES) The cells of RES 
preferentially take up the vesicles. The uptake of niosomes 
by the cells is also by circulating serum factors known as 
opsonins, which mark them for clearance. Such localized 
drug accumulation has, however, been exploited in 
treatment of animal tumors known to metastasize to the 
liver and spleen and in parasitic infestation of liver32. 
To organs other than RES 
It has been suggested that carrier system can be directed to 
specific sites in the body by use of antibodies. 
Immunoglobulins seem to bind quite readily to the lipid 
surface, thus offering a convenient means for targeting of 
drug carrier33. Many cells possess the intrinsic ability to 
recognize and bind particular carbohydrate determinants 
and this can be exploited to direct carriers system to 
particular cells. 
Neoplasia 
Doxorubicin, the anthracyclic antibiotic with broad 
spectrumanti tumor activity, shows a dose dependant 
irreversible cardio toxic effect. Niosomal delivery of this 
drug to mice bearing S-180 tumor increased their life span 
and decreased the rate of proliferation of sarcoma34. 
Niosomal entrapment increased the half-life of the drug, 
prolonged its circulation and altered its metabolism. 
Intravenous administration of methotrexate entrapped in 
niosomes to S-180 tumor bearing mice resulted in total 
regression of tumor and also higher plasma level and 
slower elimination. 
Leishmaniasis 
Niosomes can be used for targeting of drug in the 
treatment of diseases in which the infecting organism 
resides in the organ of reticuloendothelial system. 
Leishmaniasis is such a disease in which parasite invades 
cells of liver and spleen. The commonly prescribed drugs 
are antimonials, which are related to arsenic, and at high 
concentration they damage the heart, liver and kidney. 
The study of antimony distribution in mice, performed by 
Hunter et al showed high liver level after intravenous 
administration of the carrier forms of the drug. 
Delivery of peptide drugs 
Yoshida et al 35 investigated oral delivery of 9-
desglycinamide, 8- arginine vasopressin entrapped in 
niosomes in an in-vitro intestinal loop model and reported 
that stability of peptide increased significantly. 
Immunological application of niosomes 
Niosomes have been used for studying the nature of the 
immune response provoked by antigens. Brewer and 
Alexander have reported niosomes as potent adjuvant in 
terms of immunological selectivity, low toxicity and 
stability36. 
Niosomes as carriers for Hemoglobin 
Niosomes can be used as a carrier for hemoglobin. 
Niosomal suspension shows a visible spectrum 
superimposable onto that of free hemoglobin. Vesicles are 
permeable to oxygen and hemoglobin dissociation curve 
can be modified similarly to non-encapsulated 
hemoglobin37. 
Transdermal delivery of drugs by niosomes 
Slow penetration of drug through skin is the major 
drawback of transdermal route of delivery. An increase in 
the penetration rate has been achieved by transdermal 
delivery of drug incorporated in niosomes. Jayraman et al 
has studied the topical delivery of erythromycin from 
various formulations including niosomes or hairless 
mouse. From the studies, and confocal microscopy, it was 
seen that non-ionic vesicles could be formulated to target 
pilosebaceous glands. 
CONCLUSION 
Niosomal drug delivery systems are an example of one of 
the various drug delivery systems available. Niosomes 
appeared to be a well preferred drug delivery system over 
liposome as niosomes being stable and economic. The 
technology utilized in niosomes is still greatly in its 
infancy, and already it is showing promise in the fields of 
cancer and infectious disease treatments. Niosomes 
represent a promising drug delivery technology and much 
research has to be inspired in this to juice out all the 
potential in this novel drug delivery system. 
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